GALECTIN THERAPEUTICS (GALT) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$3.94
+8.2% on the day
-17.1% over 12 months
52-week range $2.08 – $6.51
Share price and insider trades
GALT closeInsider buyInsider sale
Bought, 12 months$59K
Sold, 12 months$7.0M
Insiders buying1
Insiders selling6
GALECTIN THERAPEUTICS insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $59K and 6 sold $7.0M of GALT stock on the open market.
Get emailed when insiders cluster-buy stocks like GALT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
GALT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $83K | 1 |
| Q2 2026 | — | 0 | $438K | 7 |
| Q1 2026 | $810 | 1 | $787K | 9 |
| Q4 2025 | $64K | 5 | $5.7M | 52 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit+$7KOn all tracked purchases +11.0%
Summary
Over the past 12 months, 1 GALECTIN THERAPEUTICS INC insider reported open-market purchases totaling $59K, while 6 insiders reported sales totaling $7.0M. Among insiders with enough purchase history to measure, Kevin D Freeman (Director) has the highest Insider Score at 12. 61 of 69 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 16SEC | Khurram JamilChief Medical Officer | Sell Plan | 16,250 | $5.13 | $83K | -23.2% | — |
| Jun 30SEC | Khurram JamilChief Medical Officer | Sell Plan | 47,467 | $5.04 | $239K | -21.8% | — |
| Jun 30SEC | Harold H. ShlevinDirector | Sell Plan | 22,2686,500 held (−77%) | $5.04 | $112K | -21.8% | — |
| Jun 30SEC | Harold H. ShlevinDirector | Sell Plan | 7,7326,500 held (−54%) | $5.00 | $39K | -21.2% | — |
| Jun 30SEC | Khurram JamilChief Medical Officer | Sell Plan | 2,533 | $5.00 | $13K | -21.2% | — |
| Jun 30SEC | Khurram JamilChief Medical Officer | Sell Plan | 2,037 | $5.00 | $10K | -21.2% | — |
| Jun 25SEC | Khurram JamilChief Medical Officer | Sell Plan | 7,557 | $3.14 | $24K | +25.5% | — |
| May 28SEC | Khurram JamilChief Medical Officer | Sell Plan | 568 | $3.10 | $2K | +27.1% | — |
| Feb 9SEC | Kary EldredDirector | Buy | 30065,682 held (+0%) | $2.70 | $810 | +45.9% | — |
| Jan 6SEC | Joel LewisCEO, President | Sell Plan | 37,698832,592 held (−4%) | $3.58 | $135K | +10.1% | — |
| Jan 6SEC | Joel LewisCEO, President | Sell Plan | 27,731870,290 held (−3%) | $3.91 | $108K | +0.8% | — |
| Jan 6SEC | Jack W CallicuttCFO | Sell Plan | 25,73227,968 held (−48%) | $3.90 | $100K | +1.0% | — |
| Jan 6SEC | Khurram JamilChief Medical Officer | Sell Plan | 25,49921,446 held (−54%) | $3.90 | $99K | +1.0% | — |
| Jan 6SEC | Khurram JamilChief Medical Officer | Sell Plan | 21,446 | $3.65 | $78K | +7.9% | — |
| Jan 6SEC | Joel LewisCEO, President | Sell Plan | 18,571898,021 held (−2%) | $4.20 | $78K | -6.2% | — |
| Jan 6SEC | Jack W CallicuttCFO | Sell Plan | 20,3547,614 held (−73%) | $3.67 | $75K | +7.4% | — |
| Jan 6SEC | Jack W CallicuttCFO | Sell Plan | 13,91453,700 held (−21%) | $4.20 | $58K | -6.2% | — |
| Jan 6SEC | Khurram JamilChief Medical Officer | Sell Plan | 13,05546,945 held (−22%) | $4.20 | $55K | -6.2% | — |
| Jan 5SEC | Khurram JamilChief Medical Officer | Sell Plan | 8,125 | $4.07 | $33K | -3.2% | — |
| Dec 23SEC | Kevin D FreemanDirector | Buy | 5,50055,269 held (+11%) | $3.55 | $20K | +11.0% | 12 |
| Dec 23SEC | Kevin D FreemanDirector | Buy | 5,50055,269 held (+11%) | $3.55 | $20K | +11.0% | 12 |
| Dec 23SEC | Kevin D FreemanDirector | Buy | 5,50055,269 held (+11%) | $3.55 | $20K | +11.0% | 12 |
| Dec 23SEC | Kary EldredDirector | Buy | 70065,382 held (+1%) | $3.73 | $3K | +5.6% | — |
| Dec 23SEC | Kary EldredDirector | Buy | 70065,382 held (+1%) | $3.73 | $3K | +5.6% | — |
| Dec 19SEC | Harold H. ShlevinDirector | Sell Plan | 19,79311,206 held (−64%) | $7.04 | $139K | -44.0% | — |
| Dec 19SEC | Khurram JamilChief Medical Officer | Sell Plan | 8,500 | $7.04 | $60K | -44.0% | — |
| Dec 19SEC | Joel LewisCEO, President | Sell Plan | 7,829832,592 held (−1%) | $7.06 | $55K | -44.2% | — |
| Dec 19SEC | Khurram JamilChief Medical Officer | Sell Plan | 6,463 | $7.04 | $45K | -44.0% | — |
| Dec 19SEC | Harold H. ShlevinDirector | Sell Plan | 4,7066,500 held (−42%) | $7.04 | $33K | -44.0% | — |
| Dec 19SEC | Khurram JamilChief Medical Officer | Sell Plan | 4,479 | $7.04 | $32K | -44.0% | — |
| Dec 18SEC | James C Czirr10% Owner | Sell | 30,6815,614,457 held (−1%) | $6.66 | $204K | -40.8% | — |
| Dec 16SEC | Harold H. ShlevinDirector | Sell Plan | 19,79311,206 held (−64%) | $6.27 | $124K | -37.2% | — |
| Dec 16SEC | Harold H. ShlevinDirector | Sell Plan | 8,41711,206 held (−43%) | $6.30 | $53K | -37.5% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 35,00011,206 held (−76%) | $6.02 | $211K | -34.6% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 35,00011,206 held (−76%) | $5.95 | $208K | -33.8% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 25,00011,206 held (−69%) | $5.95 | $149K | -33.8% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 20,00011,206 held (−64%) | $6.00 | $120K | -34.3% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 20,00011,206 held (−64%) | $5.96 | $119K | -33.9% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 20,00011,206 held (−64%) | $5.96 | $119K | -33.9% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 16,79011,206 held (−60%) | $6.27 | $105K | -37.2% | — |
| Dec 10SEC | Harold H. ShlevinDirector | Sell Plan | 4,00011,206 held (−26%) | $6.01 | $24K | -34.4% | — |
| Dec 8SEC | 10X Capital Management, Llc10% Owner | Sell | 132,0695,670,138 held (−2%) | $5.73 | $757K | -31.2% | — |
| Dec 8SEC | 10X Capital Management, Llc10% Owner | Sell | 30,0005,802,207 held (−1%) | $5.47 | $164K | -28.0% | — |
| Dec 4SEC | 10X Capital Management, Llc10% Owner | Sell | 120,0005,682,207 held (−2%) | $5.73 | $688K | -31.2% | — |
| Dec 4SEC | 10X Capital Management, Llc10% Owner | Sell | 30,0005,802,207 held (−1%) | $5.47 | $164K | -28.0% | — |
| Nov 19SEC | Jack W CallicuttCFO | Sell Plan | 28,1007,614 held (−79%) | $6.22 | $175K | -36.7% | — |
| Nov 19SEC | Jack W CallicuttCFO | Sell Plan | 19,7017,614 held (−72%) | $6.03 | $119K | -34.7% | — |
| Nov 19SEC | Jack W CallicuttCFO | Sell Plan | 18,2107,614 held (−71%) | $6.22 | $113K | -36.7% | — |
| Nov 19SEC | Joel LewisCEO, President | Sell Plan | 15,680832,592 held (−2%) | $6.04 | $95K | -34.8% | — |
| Nov 19SEC | Jack W CallicuttCFO | Sell Plan | 9,5867,614 held (−56%) | $6.03 | $58K | -34.7% | — |
| Nov 19SEC | Joel LewisCEO, President | Sell Plan | 6,783832,592 held (−1%) | $6.15 | $42K | -35.9% | — |
| Nov 19SEC | Jack W CallicuttCFO | Sell Plan | 2,3237,614 held (−23%) | $6.03 | $14K | -34.7% | — |
| Nov 14SEC | Khurram JamilChief Medical Officer | Sell Plan | 41,5004,479 held (−90%) | $5.47 | $227K | -28.0% | — |
| Nov 14SEC | Khurram JamilChief Medical Officer | Sell Plan | 41,5004,479 held (−90%) | $5.47 | $227K | -28.0% | — |
| Nov 14SEC | Khurram JamilChief Medical Officer | Sell Plan | 21,8674,479 held (−83%) | $5.47 | $120K | -28.0% | — |
| Nov 14SEC | Khurram JamilChief Medical Officer | Sell Plan | 16,2504,479 held (−78%) | $5.47 | $89K | -28.0% | — |
| Nov 12SEC | 10X Capital Management, Llc10% Owner | Sell | 40,0005,832,207 held (−1%) | $5.25 | $210K | -25.0% | — |
| Nov 12SEC | Jack W CallicuttCFO | Sell Plan | 1,8807,614 held (−20%) | $6.02 | $11K | -34.6% | — |
| Nov 12SEC | Joel LewisCEO, President | Sell Plan | 1,867832,592 held (−0%) | $6.03 | $11K | -34.7% | — |
| Nov 12SEC | Jack W CallicuttCFO | Sell Plan | 1,7367,614 held (−19%) | $6.03 | $10K | -34.7% | — |
| Nov 12SEC | Jack W CallicuttCFO | Sell Plan | 1,6757,614 held (−18%) | $6.03 | $10K | -34.7% | — |
| Nov 7SEC | Jack W CallicuttCFO | Sell Plan | 2007,614 held (−3%) | $6.00 | $1K | -34.3% | — |
| Nov 7SEC | Jack W CallicuttCFO | Sell Plan | 2007,614 held (−3%) | $6.00 | $1K | -34.3% | — |
| Nov 7SEC | Jack W CallicuttCFO | Sell Plan | 2007,614 held (−3%) | $6.00 | $1K | -34.3% | — |
| Nov 7SEC | Joel LewisCEO, President | Sell Plan | 200832,592 held (−0%) | $6.00 | $1K | -34.3% | — |
| Nov 5SEC | Joel LewisCEO, President | Sell Plan | 14,420832,592 held (−2%) | $6.07 | $88K | -35.1% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 10,7417,614 held (−59%) | $6.07 | $65K | -35.1% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 8,9747,614 held (−54%) | $6.07 | $54K | -35.1% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 8,9147,614 held (−54%) | $6.07 | $54K | -35.1% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 1,3007,614 held (−15%) | $6.01 | $8K | -34.4% | — |
| Nov 5SEC | Joel LewisCEO, President | Sell Plan | 1,300832,592 held (−0%) | $6.01 | $8K | -34.4% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 1,2607,614 held (−14%) | $6.01 | $8K | -34.4% | — |
| Nov 5SEC | Jack W CallicuttCFO | Sell Plan | 1,2507,614 held (−14%) | $6.01 | $8K | -34.4% | — |
| Oct 24SEC | 10X Capital Management, Llc10% Owner | Sell | 30,0005,872,207 held (−1%) | $4.94 | $148K | -20.2% | — |
| Oct 24SEC | 10X Capital Management, Llc10% Owner | Sell | 20,0005,902,207 held (−0%) | $4.93 | $99K | -20.1% | — |
Insiders at GALECTIN THERAPEUTICS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| 10X Capital Management, Llc10% Owner | — | $2.2M | Dec 8, 2025 | — |
| Harold H. ShlevinDirector | — | $1.6M | Jun 30, 2026 | — |
| Khurram JamilChief Medical Officer | — | $1.4M | Jul 16, 2026 | — |
| Jack W CallicuttCFO | — | $944K | Jan 6, 2026 | — |
| Joel LewisCEO, President | — | $621K | Jan 6, 2026 | — |
| James C Czirr10% Owner | — | $204K | Dec 18, 2025 | — |
| Kevin D FreemanDirector | $59K | — | Dec 23, 2025 | 12 |
| Kary EldredDirector | $6K | — | Feb 9, 2026 | — |
GALT stock: common questions
Are GALECTIN THERAPEUTICS INC insiders buying GALT stock?
In the past 12 months, 1 insiders reported open-market purchases of GALT worth $59K. The latest was Director Kary Eldred bought $810 of GALT at $2.70.
Are GALECTIN THERAPEUTICS INC insiders selling GALT stock?
6 insiders reported sales worth $7.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is GALT's 52-week range?
Over the past year GALT has traded between $2.08 and $6.51. It last closed at $3.94 on Oct 9, 2026.